0.8979

5.46% -0.0519

After Hours: .86 -0.0379 -4.22%

Neurosense Therapeutics Ltd (NRSN)

Overview News Price History Discussions Forecast

Neurosense Therapeutics Ltd stock is traded at $0.8979, with a volume of 441.92K. It is down -5.46% in the last 24 hours and up +17.83% over the past month. NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Previous Close:

$0.9498

Open:

$0.9759

24h Volume:

441.92K

Relative Volume:

2.66

Market Cap:

$32.41M

Revenue:

Net Income/Loss:

$-10.21M

P/E Ratio:

-1.537

EPS:

-0.5842

Net Cash Flow:

1W Performance:

+11.80%

1M Performance:

+17.83%

6M Performance:

-12.82%

1Y Performance:

-12.90%

1-Day Range:

$0.8005

$0.9759

1-Week Range:

$0.8005

$0.9759

52-Week Range:

$0.63

$2.60

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name

Neurosense Therapeutics Ltd

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-06-30

Latest SEC Filings

NRSN's Discussions on Twitter

Compare NRSN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRSN Neurosense Therapeutics Ltd	0.8979	34.29M	0	-10.21M	0	-0.5842
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Neurosense Therapeutics Ltd Stock (NRSN) Latest News

Apr 28, 2026

NeuroSense Announces Pricing of Insider-Led PIPE Financing - The Malaysian Reserve

Apr 28, 2026

NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price - TipRanks

Apr 28, 2026

NeuroSense (Nasdaq: NRSN) insiders lead $600K PIPE financing at premium - Stock Titan

Apr 28, 2026

Apr 27, 2026

NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding - marketscreener.com

Apr 27, 2026

Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo

Apr 27, 2026

Apr 25, 2026

NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones - The Globe and Mail

Apr 25, 2026

Apr 24, 2026

NeuroSense (NRSN) CMO steps down but stays on as advisor for PrimeC - Stock Titan

Apr 24, 2026

Apr 18, 2026

Tangible book value per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Apr 17, 2026

EBIT per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Apr 17, 2026

Operating cash flow per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Apr 17, 2026